论文部分内容阅读
目的研究雌激素受体GPR30与泌乳素腺瘤侵袭性的相关性。方法本实验收集临床确诊泌乳素腺瘤患者40例,分为侵袭性组和非侵袭性组,采用免疫组化及HPF半定量方法研究GPR30的表达水平在侵袭性和非侵袭性泌乳素腺瘤中的表达差异。结果泌乳素腺瘤中均有GPR30蛋白的表达,侵袭组和非侵袭组表达的强度比较差异有统计学意义(P<0.05),在非侵袭组中免疫组化染色呈黄褐色,阳性平均值高,多为强阳性;侵袭组免疫组化染色呈淡黄色,阳性平均值低,多为弱阳性,两者数值比较差异有统计学意义(P<0.05)。结论 GPR30蛋白表达与泌乳素腺瘤侵袭性密切相关,可作为评判泌乳素垂体瘤侵袭性的分子生物学标志物。
Objective To study the relationship between the estrogen receptor GPR30 and the aggressiveness of prolactinomas. Methods Forty patients with clinically confirmed prolactinomas were enrolled in this study. They were divided into invasive group and noninvasive group. The expression of GPR30 was detected by immunohistochemistry and HPF semi-quantitative method in both invasive and non-invasive prolactinomas In the expression differences. Results The expression of GPR30 protein in both prolactinomas was significantly different (P <0.05). The expression of GPR30 in both invasive and non-invasive groups was statistically significant (P <0.05) High, mostly strong positive; invasion group was light yellow immunohistochemical staining, the positive average low, mostly weakly positive, the difference between the two values were statistically significant (P <0.05). Conclusion The expression of GPR30 protein is closely related to the aggressiveness of prolactinomas and may be used as a molecular biomarker to evaluate the invasiveness of prolactin pituitary tumors.